A focused team driving transformational change through wide-ranging collaborations, deep scientific expertise, and a technology-forward mind-set.

Technology that Raises the Standard of Care

Voximetry is a Healthtech software company committed to advancing dosimetry-guided Radiopharmaceutical Therapy (DG-RPT). With Torch™, we aim to improve patient outcomes by moving beyond population based models and making it simpler for clinicians to develop patient-specific RPT treatment options.

Executive Leadership

Sue Wallace, PhD

Chief Executive Officer
& Executive Board Chair

A 30-year veteran of the radiation sciences with global leadership experience at GE Healthcare, Cardinal Health, and Philips. A PhD in Radiopharmaceutical Chemistry and Six Sigma Master Black Belt, Sue is the strategic architect of Voximetry’s dual-market platform.

Fred Wilson, MSc

Chief Scientific Officer

Fred has over 20 years of experience as a medical physicist with an MA and MSci from the University of Cambridge, and an MSc in Medical Physics from the University of Exeter. He is currently a Fellow of the Institute of Physics (IoP) and the Institute of Physics and Engineering in Medicine (IPEM).

Paul Wickre, MS

Chief Technology Officer
Board Director
Co-Founder

Paul has spent over 25 years commercializing software for treatment planning and quality assurance at Philips Radiation Oncology Systems and Standard Imaging and has been developing radiation treatment planning software for the past 13 years under strict FDA regulatory guidelines.

Board of Directors & Key Advisors

Rick Wolfen

Board Director

Rick is an experienced investor and strategic leader. He is the Managing Member of Sea Glass Ventures, an early-stage venture capital fund and was President & Founder of Rock Asset Management – a commercial real estate investment and management company. Rick holds a number of board positions, and is active in philanthropy through the Wolfen Family Foundation.

Frances Johnson, MD

Board Director

Dr. Johnson has held executive roles at Perspective Therapeutics and Viewpoint Molecular Targeting. As a physician scientist and entrepreneur, she has led academic programs and founded two Healthtech companies, successfully scaling them through equity rounds or public exits.

Richard L Wahl, MD

Chair of Scientific & Clinical Advisory Board

Dr. Wahl was among the first to precisely target internal radiation therapy to cancers. He has a successful track record of innovation from the pre-clinical stage to the clinical environment. His significant translational success includes 20 patents, 2 FDA approved cancer treatments and at least 3 FDA approved devices. Dr. Wahl is Director of the Mallinckrodt Institute of Radiology at Washington University School of Medicine, Head of the Department of Radiology, and a Professor of Radiation Oncology.

Bryan Bednarz, PhD

Scientific Advisor
Co-Founder

Bryan has over 15 years of experience in radiation transport methods, dosimetry and medical device development. Bryan is a tenured Associate Professor in the Department of Medical Physics at the University of Wisconsin-Madison.